logo

For the Inventor, By the Inventor

Ruxton, MD, United States of America

Mackenzie Walser

This inventor holds 14 USPTO granted patents. Top assignees: Johns Hopkins University, Synthelabo. Active years: 1978-2004.

USPTO Granted Patents = 14

% Patents Active = 100.0

Average Co-Inventor Count = 1.1

ph-index = 10

Forward Citations = 289(Granted Patents)


Location History:

  • Ruxton, MD (US) (1978 - 1997)
  • Baltimore, MD (US) (2004)

Company Filing History:

goldMedal14 out of 3,795 
 
Johns Hopkins University
 patents
silverMedal1 out of 252 
 
Synthelabo
 patents
where one patent can have more than one assignee

Years Active: 1978-2004

Loading Chart...
14 patents (USPTO):Explore Patents
1. 6713501 - Supplement for dialysis patients (2004-03-30),
2. 5591736 - Method of retarding the progression of chronic renal failure (1997-01-07),
3. 5432176 - Method of retarding the progression of chronic renal failure (1995-07-11),
4. 5354771 - Methods for treatment of sepsis using branch chain amino acids (1994-10-11),
5. 5175144 - Method of retarding the progression of chronic renal failure (1992-12-29),
6. 4752619 - Nutritional supplement for treatment of uremia (1988-06-21),
7. 4677121 - Method of inhibiting muscle protein degradation (1987-06-30),
8. 4352814 - Treatment of hepatic and renal disorders with mixed salts of essential (1982-10-05),
9. 4320146 - Treatment of hepatic and renal disorders with ornithine and arginine (1982-03-16),
10. 4296127 - Mixed salts of essential or semi-essential amino acids and nitrogen-free (1981-10-20),
11. 4228099 - Ornithine and arginine salts of branched chain keto acids and uses in (1980-10-14),
12. 4100293 - Treatment of hepatic disorders with therapeutic compositions comprising (1978-07-11),
13. 4100161 - Promotion of protein synthesis and suppression of urea formation in the (1978-07-11),
14. 4100160 - Therapeutic compositions comprising alpha-hydroxy analogs of essential (1978-07-11),

Title: Mackenzie Walser: Innovator in Renal Health

Introduction

Mackenzie Walser is a prominent inventor based in Ruxton, Maryland, known for her significant contributions to renal health. With a total of 14 patents to her name, she has made remarkable strides in developing solutions for patients undergoing dialysis and those suffering from chronic renal failure.

Latest Patents

Among her latest patents is a supplement specifically designed for dialysis patients. This innovative tablet diet supplement comprises a mixture of essential amino acids, including L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-tyrosine, and L-valine. It aims to prevent and/or correct hypoalbuminemia in patients on dialysis. Another notable patent focuses on a method for retarding the progression of chronic renal failure. This method involves the administration of dehydroepiandrosterone (DHEA) in effective amounts, preferably through oral intake at a dose of about 400 to 1600 mg/day. It is recommended that patients suffering from severe chronic renal failure maintain a protein-restricted diet during DHEA administration.

Career Highlights

Mackenzie has worked with esteemed institutions, including The Johns Hopkins University and Synthelabo. Her work in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Daniel G. Sapir and Peter M. Stewart. Their collaborative efforts have further advanced the understanding and treatment of renal health issues.

Conclusion

Mackenzie Walser's innovative work in renal health has led to significant advancements in the treatment of dialysis patients and those with chronic renal failure. Her contributions continue to impact the field positively, showcasing her dedication to improving patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…